What to know before you count on PRP made by spinning your blood

What to ask when someone says PRP works

The letters PRP mean platelet-rich plasma; a clinician draws and spins blood from your arm. The spinning gathers platelets, which are little blood pieces that help stop bleeding.

A careful study compares people who received PRP with people who received different care, then checks whether both groups had less soreness and easier movement. The same questions are asked of everyone.

Ask if the people studied had your same joint and cause of soreness. A knee result won’t always fit someone with a sore shoulder.

People sometimes improve as a sore spell settles on its own. Ask whether PRP brought more relief or easier movement than the other care.

Cortisone may ease soreness earlier, while some PRP results appear later. You’ll want to know when people were checked and how much better they felt.

What to write down before deciding

Keep a simple note of what hurts and which care helps across one ordinary day. You don’t need a chart or a special form.

Write how long any relief lasts and whether walking or sleep gets easier. Those changes matter more than a small score on a test.

You may also ask how many people felt a change large enough to notice. It’s fair to request a plain answer that you can use.

While you decide, continue gentle movement that feels comfortable. Cold or warmth may help, but you’ll want to stop when sharp pain begins.

Take your notes and old reports to the visit. You’ll be ready to talk about the daily needs that matter to you.

For Chandler residents, QC Kinetix has medical providers who check your joint, then discuss regenerative treatments such as PRP, which is made by drawing blood from your arm and spinning it.

Sources

1. RESTORE, the largest and most rigorously blinded placebo-controlled PRP trial in knee OA (n=288, participant-, injector- and assessor-blinded), gave three weekly injections of a commercial leukocyte-poor PRP or saline. At 12 months the change in knee pain was -2.1 vs -1.8 points (difference -0.4; 95% CI -0.9 to 0.2; P=.17) and the change in medial tibial cartilage volume was -1.4% vs -1.2% (difference -0.2%; P=.81). Twenty-nine of 31 prespecified secondary outcomes showed no between-group difference. The authors concluded the findings do not support the use of PRP for knee OA.

   Bennell KL, et al. — Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.. JAMA, 2021. DOI: 10.1001/jama.2021.19415.

2. A network meta-analysis restricted to LARGE randomized trials (at least 100 patients per group; 57 RCTs, 22,795 participants, 18 intra-articular interventions) found treatment effects were consistently larger in the 35 high-risk-of-bias trials than in the 22 low/unclear-risk trials. In the main analysis excluding high-risk trials, triamcinolone had the highest probability of exceeding the minimal important difference at weeks 2 and 6; hyaluronic acid had no effect on pain (SMD -0.04, 95% CrI -0.19 to 0.11, 11 trials) but higher odds of dropouts due to adverse events (OR 2.01) and of serious adverse events (OR 1.86). The effects of 16 of the 18 interventions were smaller than the MID and most were consistent with placebo effects.

   Pereira TV, et al. — Effectiveness and safety of intra-articular interventions for knee and hip osteoarthritis based on large randomized trials: A systematic review and network meta-analysis.. Osteoarthritis and Cartilage, 2025. DOI: 10.1016/j.joca.2024.08.014.

3. The largest head-to-head trial of cell-based orthobiologics to date randomised 480 patients with KL II-IV knee OA across four arms: autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction, allogeneic umbilical cord tissue-derived MSCs, and a corticosteroid injection control. At 12 months NONE of the three orthobiologic injections was superior to another or to the corticosteroid control on either co-primary endpoint (VAS pain, KOOS pain), and none of the four groups showed a significant change in MRI osteoarthritis score from baseline. No procedure-related serious adverse events were reported.

   Mautner K, et al. — Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial.. Nature Medicine, 2023. DOI: 10.1038/s41591-023-02632-w.

4. The ESSKA-ORBIT European consensus on blood-derived orthobiologics graded 28 question-statement sets; only 9 of 28 had high-level scientific support. Three statements reached grade A: that there is enough preclinical and clinical evidence to support PRP use in knee OA; that clinical evidence shows effectiveness in MILD TO MODERATE knee OA (KL grade 3 or lower); and that PRP provides a longer effect than the short-term effect of corticosteroid with a safer profile. The panel regarded PRP as a valid and possible first-line injectable option for KL grades 1-3.

   Laver L, et al. — The use of injectable orthobiologics for knee osteoarthritis: A European ESSKA-ORBIT consensus. Part 1-Blood-derived products (platelet-rich plasma).. Knee Surgery, Sports Traumatology, Arthroscopy, 2024. DOI: 10.1002/ksa.12077.

5. A meta-analysis of 11 RCTs (730 patients) with lateral epicondylitis found the timing reverses the answer: corticosteroid was significantly BETTER than PRP in the short term (under 2 months: VAS mean difference 0.93 favouring steroid; DASH 10.23 favouring steroid), the two did not differ at 2-6 months, and PRP was significantly better at 6 months or more (VAS -2.18; DASH -8.13; Mayo Elbow +16.53).

   Xu Y, et al. — Platelet-Rich Plasma Has Better Results for Long-term Functional Improvement and Pain Relief for Lateral Epicondylitis: A Systematic Review and Meta-analysis of Randomized Controlled Trials.. American Journal of Sports Medicine, 2024. DOI: 10.1177/03635465231213087.

6. A 2026 network meta-analysis of 21 RCTs (2,254 patients) found both leukocyte-rich and leukocyte-poor PRP significantly superior to placebo and to hyaluronic acid for function at 6-12 months (MD vs placebo -13.20 and -10.54 respectively). LP-PRP ranked highest (P-score 0.96) but the DIRECT comparison between the two formulations showed no statistically significant difference, and the authors concluded there is insufficient evidence to recommend one PRP formulation over the other.

   Xu B, et al. — Leukocyte-rich versus leukocyte-poor platelet-rich plasma and hyaluronic acid for knee osteoarthritis: a systematic review and network meta-analysis.. Journal of Orthopaedic Surgery and Research, 2026. DOI: 10.1186/s13018-026-06689-4.